Wall Street Analysts See a 50.79% Upside in Castle Biosciences (CSTL): Can the Stock Really Move This High?

Group 1 - Castle Biosciences, Inc. (CSTL) shares have increased by 2.1% over the past four weeks, closing at $27.19, with a mean price target of$41 indicating a potential upside of 50.8% [1] - The average price targets from analysts range from a low of $32 to a high of$50, with a standard deviation of $5.22, suggesting a variability in estimates [2] - Analysts show strong agreement on CSTL's ability to report better earnings than previously predicted, which supports the potential for stock upside [4][9] Group 2 - The Zacks Consensus Estimate for CSTL has increased by 17.9% due to two upward revisions in earnings estimates over the last 30 days, with no negative revisions [10] - CSTL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [11] - While consensus price targets may not be reliable for predicting the extent of gains, they can provide a directional guide for price movement [12]